How can recombinant adeno-associated virus (rAAV) vector technology be empowered with biofabrication strategies in its translation towards the clinic?

M. de Ruijter

doi:10.1016/j.joca.2022.12.005

How can recombinant adeno-associated virus (rAAV) vector technology be empowered with biofabrication strategies in its translation towards the clinic?

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	421-422
Number of pages	2
Journal	Osteoarthritis and Cartilage
Volume	31
Issue number	4
DOIs	https://doi.org/10.1016/j.joca.2022.12.005
Publication status	Published - Apr 2023

Access to Document

10.1016/j.joca.2022.12.005

Cite this

@article{e8b42012300644eeb28b53a9ebbe7fce,

title = "How can recombinant adeno-associated virus (rAAV) vector technology be empowered with biofabrication strategies in its translation towards the clinic?",

author = "{de Ruijter}, M.",

year = "2023",

month = apr,

doi = "10.1016/j.joca.2022.12.005",

language = "English",

volume = "31",

pages = "421--422",

journal = "Osteoarthritis and Cartilage",

issn = "1063-4584",